Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

Charehbili A, de Groot S, van der Straaten T, Swen JJ, Pijl H, Gelderblom H, van de Velde CJ, Nortier JW, Guchelaar HJ, Kroep JR.

Pharmacogenomics. 2015;16(11):1267-76. doi: 10.2217/PGS.15.74. Epub 2015 Aug 20.

PMID:
26289095
2.

CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.

Zhou X.

Clin Breast Cancer. 2014 Apr;14(2):e33-40. doi: 10.1016/j.clbc.2013.11.001. Epub 2013 Nov 22.

PMID:
24393851
3.

Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients.

Faraji A, Dehghan Manshadi HR, Mobaraki M, Zare M, Houshmand M.

PLoS One. 2016 Dec 30;11(12):e0168519. doi: 10.1371/journal.pone.0168519. eCollection 2016.

4.

Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.

Sugishita M, Imai T, Kikumori T, Mitsuma A, Shimokata T, Shibata T, Morita S, Inada-Inoue M, Sawaki M, Hasegawa Y, Ando Y.

Breast Cancer. 2016 Mar;23(2):195-201. doi: 10.1007/s12282-014-0547-x. Epub 2014 Jul 10.

PMID:
25008867
5.

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).

McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF; Australia and New Zealand Breast Cancer Trials Group.

Breast. 2014 Apr;23(2):142-51. doi: 10.1016/j.breast.2013.12.001. Epub 2014 Jan 3.

6.

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.

Pfeil AM, Vulsteke C, Paridaens R, Dieudonné AS, Pettengell R, Hatse S, Neven P, Lambrechts D, Szucs TD, Schwenkglenks M, Wildiers H.

BMC Cancer. 2014 Mar 19;14:201. doi: 10.1186/1471-2407-14-201.

7.

Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study.

Ishikawa T, Sakamaki K, Narui K, Kaise H, Tsugawa K, Ichikawa Y, Mukai H; for Comprehensive Support Project for Oncological Research of Breast Cancer.

Jpn J Clin Oncol. 2016 Jul;46(7):692-5. doi: 10.1093/jjco/hyw045. Epub 2016 May 9.

PMID:
27162322
8.

A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.

George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, Sunder E.

Clin Breast Cancer. 2009 Aug;9(3):161-5. doi: 10.3816/CBC.2009.n.026.

PMID:
19661039
9.

A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.

Wu L, Yao L, Zhang H, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Yin CC, Xie Y.

Oncotarget. 2016 Jan 26;7(4):5042-52. doi: 10.18632/oncotarget.5837.

10.

Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.

Le Morvan V, Litière S, Laroche-Clary A, Ait-Ouferoukh S, Bellott R, Messina C, Cameron D, Bonnefoi H, Robert J.

Pharmacogenomics J. 2015 Feb;15(1):63-8. doi: 10.1038/tpj.2014.24. Epub 2014 Jun 24.

PMID:
24958282
11.

Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients.

Ji M, Tang J, Zhao J, Xu B, Qin J, Lu J.

Cancer Biol Ther. 2012 Mar;13(5):264-71. doi: 10.4161/cbt.18920. Epub 2012 Mar 1.

12.

ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY.

Cancer Sci. 2015 Jan;106(1):86-93. doi: 10.1111/cas.12560. Epub 2014 Dec 8.

13.

CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A.

Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30.

PMID:
21960110
14.

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C.

J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi: 10.1200/JCO.2014.55.7876. Epub 2014 Sep 8.

PMID:
25199759
15.

Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer.

Ishitobi M, Komoike Y, Motomura K, Koyama H, Inaji H.

Oncology. 2010;78(3-4):213-9. doi: 10.1159/000313702. Epub 2010 Apr 26.

PMID:
20424493
16.

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group.

J Clin Oncol. 2004 Jul 1;22(13):2587-93.

PMID:
15226326
17.

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.

N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065.

18.

High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.

Callens C, Debled M, Delord M, Turbiez-Stalain I, Veyret C, Bièche I, Brain E.

Breast Cancer Res Treat. 2015 Sep;153(2):383-9. doi: 10.1007/s10549-015-3552-7. Epub 2015 Aug 29.

PMID:
26318989
20.

FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.

Marmé F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, Lichter P, Hahn M, Schneeweiss A.

Ann Oncol. 2010 Aug;21(8):1636-42. doi: 10.1093/annonc/mdq017. Epub 2010 Feb 10.

PMID:
20147743

Supplemental Content

Support Center